
News|Articles|April 1, 2011
FDA Pipeline Preview, April 2011 (Salix, Protalix, Amyvid, indacaterol, Istodax, Mucin 1 targeting peptide GO-203-2c, Intercept plasma, Lomitapide, Liver cell therapy)
Recent FDA action (through, March 2011) related to Salix, Protalix, Amyvid, indacaterol, Istodax, Mucin 1 targeting peptide GO-203-2c, Intercept plasma, Lomitapide, Liver cell therapy.
Advertisement
Complete response
Recommendations for approval
Priority review
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Patients may not see savings from new Medicare drug programs
2
Sanofi acquires Dynavax for $2.2 billion to bolster vaccine portfolio
3
AHIP lays blame for rising healthcare costs on hospitals, private equity
4
Why Timing, Access and Interpretation Matter in Oncology Biomarker Testing
5




















































